Au­toim­mune biotech Kiniksa prices up­sized $152M IPO as Schol­ar Rock bags $75M for pre­clin­i­cal SMA drug

Two biotechs that have been on par­al­lel IPO tracks are blast­ing off with siz­able sup­port for their Nas­daq de­buts.

Kiniksa got the bulki­er raise among the two, reap­ing $152 mil­lion at $18 a share — up from the $126 mil­lion it was look­ing for — by of­fer­ing 8.44 mil­lion shares, or 21% more than orig­i­nal­ly planned. Schol­ar Rock, mean­while, got what it asked for, pric­ing its $75 mil­lion IPO at the mid­point of $14.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER